share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4：持股变动声明-董事 Borgeson Blake
美股sec公告 ·  07/03 16:41
Moomoo AI 已提取核心信息
Blake Borgeson, a reporting person at Recursion Pharmaceuticals, Inc. [RXRX], completed a transaction involving the grant of 1,441 shares of Class A Common Stock on July 1, 2024. The shares were acquired at no cost, indicating this was likely an award or grant. Following this transaction, Borgeson's direct holdings in the company amount to a total of 7,178,557 shares of Common Stock.
Blake Borgeson, a reporting person at Recursion Pharmaceuticals, Inc. [RXRX], completed a transaction involving the grant of 1,441 shares of Class A Common Stock on July 1, 2024. The shares were acquired at no cost, indicating this was likely an award or grant. Following this transaction, Borgeson's direct holdings in the company amount to a total of 7,178,557 shares of Common Stock.
Recursion Pharmaceuticals, Inc. [RXRX]的报告人Blake Borgeson于2024年7月1日完成了一项交易，涉及授予1441股A类普通股。股份是免费获取的，这表明很可能是奖励或授予。此次交易后，Borgeson在该公司的直接持股总数为7178557股普通股。
Recursion Pharmaceuticals, Inc. [RXRX]的报告人Blake Borgeson于2024年7月1日完成了一项交易，涉及授予1441股A类普通股。股份是免费获取的，这表明很可能是奖励或授予。此次交易后，Borgeson在该公司的直接持股总数为7178557股普通股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息